NeOnc Technologies reported a significant clinical update where a critically ill three-year-old with an aggressive brain tumor showed early improvement after receiving the investigational drug NEO100 via compassionate use in Abu Dhabi. This case highlights the potential of NEO100 and underscores NeOnc's strategy to expand its brain cancer treatments internationally, supported by regulatory approvals and strategic partnerships, including a new banking director from Abu Dhabi. The company is advancing clinical trials for NEO100 and its oral candidate NEO212, with upcoming FDA meetings expected to shape future development. This progress positions NeOnc as a notable player in central nervous system cancer therapies across global markets.
NeOnc Technologies' recent clinical update is provided here as context for readers. For those tracking health-sector stocks, 93 of 150 priced US health-sector stocks on Pluang rose today while 46 fell. AMRX was priced at USD 19.50 with a 1-day change of +1.30%, CGC was USD 0.74 with a 1-day change of +1.29% and 100% sell order activity, and TLRY was USD 3.25 with a 1-day change of +1.25% and 97% sell order activity. This data is as of Oct 16, 2026 19:01 WIB.
Whole Lotta Dank, a Canadian cannabis brand platform, has launched its first brand, Dank Pack, debuting with Blueberry BBL available across Alberta. The company is expanding its portfolio with over 20 SKUs under regulatory review and is actively seek...
Nasdaq announced that trading in CN Healthy Food Tech Group Corp.'s common stock and warrants will resume on October 19, 2026, after being halted since October 1, 2025. The resumption marks the end of a year-long trading suspension, allowing investor...
David Solomon, CEO of Goldman Sachs, has been appointed as the new chair of The Business Council, taking over from Brian Cornell, Executive Chair of Target Corporation. This leadership change comes at a critical time as the Council addresses challeng...
The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, expanding at a CAGR of 6.15%. Growth is fueled by advances in biologics, AI-driven drug discovery, specialty drugs, and manufacturing i...
SEDA Experts LLC has appointed Noor Ul Islam as Managing Director, enhancing its capabilities in risk management and securities practices. With nearly 30 years of experience at major financial institutions like Citibank and Barclays, Islam brings dee...
